Moderna stock was rising early on Monday after the Food and Drug Administration gave limited approval to the company’s newest Covid-19 vaccine. It relieves one worry for the pharmaceutical ...

The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above. Moderna expects to have the vaccine available for the 2025-2026 ...

The Food and Drug Administration (FDA) has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for specific high-risk populations, the company announced Saturday. This marks a ...

Experts warn about risks of new COVID-19 vaccine guidelines 04:32. The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12 ...

The case centered on whether Alnylam’s patents, U.S. Patent Nos. 11,246,933 and 11,382,979 were infringed by Moderna’s use of SM-102-a cationic lipid in Moderna’s COVID-19 vaccine formulations.

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to 64 years at high risk for severe disease, aligning with the agency ...

June 2, 2025 -- The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine, with some limits on who can get it.. The vaccine, called mNexspike, is for people who’ve previously received a ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing Covid shot does not currently face.

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.